在被认为是世界上第一个是什么，科学家已经开发出一套新的血液测试，肠易激综合征的诊断。诊断工具可以快速、准确地诊断疼痛的情况，提供希望世界各地数以百万计的人。目前还没有具体的测试经常被医生用来确定IBS。

　　因此，数以百万计的患者接受侵入性检查以排除其他更严重的疾病，包括肠癌和克罗恩病，在专家可以作出诊断。

　　胃肠病学家马克Pimentel博士，在雪松-西奈医学中心在洛杉矶，认为他的新方法可以确保患者的早期诊断，避免医疗预约年需要。他说，试验证实当一个人开发了IBS因食物中毒，该病的一个主要原因。细菌产生的毒素，如沙门氏菌，会严重损害健康的肠道功能的重要神经损害消化系统。新的血液测试，识别和量的特异性抗体对毒素的反应的存在。Pimentel博士说：“早期诊断意味着患者可以避免侵入性检查和专家的访问，经常让他们有更多的问题比答案年。“有了这些新的血液测试，许多患者现在能够进行正确的治疗自己的病情。” 肠易激综合征是最常见的胃肠道疾病困扰的患者在美国，影响近40000000人。

　　在英国，有五人遭受的条件，而大约10的世界人口的百分之 受到影响。Pimentel博士说，疾病已经“几乎不可能诊断直到现在。它的特点是由一个集群混杂的症状，包括慢性腹胀，腹痛，腹泻，气，和无情的较量，便秘或 。疲劳和压力的患者由于试图计划他们的生活去浴室，可以证明衰弱。

　　Pimentel博士和他的研究小组研究了近3000人相比，IBS患者诊断为炎症性肠病，乳糜泻和那些没有胃肠道疾病。血液检查发现两抗体抗CdtB和IBS患者抗粘着斑蛋白-大于90分的把握，他们发现 相关。“大多数IBS患者被告知，在同一时间或另一个疾病的心理，在他们的脑海，Pimentel博士说。“事实上，我们现在可以通过他们的血液确认疾病，不是他们的头，就要结束了很多情感痛苦的我看到这些患者忍受。”研究，验证血液测试的准确性，发表在PLoS ONE。博士还介绍了他的研究断裂在消化疾病周2015星期日在华盛顿

　　原文

　　World's first blood test that can diagnose IBS: Breakthrough could help millions avoid years of invasive tests, painful symptoms and misdiagnosis

　　In what is thought to be a world first, scientists have developed a new set of blood tests to diagnose irritable bowel syndrome.

　　The diagnostic tool can quickly and accurately diagnose the painful condition, offering hope to millions afflicted across the world.

　　There are currently no specific tests routinely used by doctors to identify IBS.

　　As a result, millions of patients undergo invasive investigations to rule out other, more serious conditions including bowel cancer and Crohn's disease, before specialists can arrive at a diagnosis.

　　Gastroenterologist Dr Mark Pimentel, at Cedars-Sinai Medical Center in LA, believes his new method could help secure an early diagnosis for patients, avoiding the need for years of medical appointments.

　　He said the tests confirm when an individual has developed IBS as a result of food poisoning, a major cause of the disorder.

　　Toxins produced by bacteria, such as salmonella, can severely harm the digestive system by damaging nerves critical to healthy gut function.

　　The new blood tests identify the presence and amount of specific antibodies reacting to the toxins.

　　Dr Pimentel said: 'Having an early diagnosis means patients can avoid years of invasive tests and visits to specialists that often leave them with more questions than answers.

　　'With these new blood tests many patients will now be able to proceed right to therapy for their condition.'

　　IBS is the most common gastroenterological disorder plaguing patients in the US, affecting nearly 40 million people.

　　In the UK, one in five people suffers the condition, while an estimated 10 per cent of the world's population are affected.

　　Dr Pimentel said the disorder has been 'nearly impossible to diagnose until now'.

　　It is characterised by a cluster of confounding symptoms, including chronic bloating, abdominal pain, gas, and bouts of relentless diarrhoea, constipation or both.

　　Fatigue and the stress patients suffer as a result of trying to plan their lives around visits to the bathroom, can prove debilitating.

　　Dr Pimentel and his team of researchers studied nearly 3,000 people, comparing IBS patients to those diagnosed with inflammatory bowel disease, coeliac disease and those with no gastrointestinal disease.

　　The blood tests identified the two antibodies associated with IBS - anti Cdtb and anti-vinculin - with greater than 90 per cent certainty, they found.

　　'Most IBS patients have been told at one time or another that the disease was psychological, all in their head,' said Dr Pimentel.

　　'The fact that we can now confirm the disease through their blood, not their head, is going to end a lot of the emotional suffering I have seen these patients endure.'

　　The study, validating the accuracy of the blood tests, was published in the journal PLOS ONE.

　　Dr Pimental also presented his research on Sunday at Digestive Disease Week 2015 in Washington D.C.